# Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors

> **NCT05768880** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Seattle Children's Hospital** · enrollment: 72 (estimated)

## Conditions studied

- Diffuse Intrinsic Pontine Glioma
- Diffuse Midline Glioma
- Recurrent CNS Tumor, Adult
- Recurrent, CNS Tumor, Childhood
- Refractory Primary Malignant Central Nervous System Neoplasm

## Interventions

- **BIOLOGICAL:** SC-CAR4BRAIN

## Key facts

- **NCT ID:** NCT05768880
- **Lead sponsor:** Seattle Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-05
- **Primary completion:** 2028-01-15
- **Final completion:** 2043-12-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05768880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05768880, "Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05768880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*